^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    garsorasib (D-1553) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    550O - Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study

    Published date:
    10/16/2023
    Excerpt:
    Combination of D-1553 and cetuximab showed an acceptable safety profile and achieved a higher response rate than D-1553 monotherapy and a promising PFS in heavily pretreated pts with KRAS G12C mutated CRC.
    Trial ID:
    KEYNOTE-C15